- Home
- XBIT vs ABVC Comparison
XBIT vs ABVC Comparison
Compare XBIT & ABVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XBIT | ABVC |
|---|---|---|
| Founded | 2005 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.2M | 58.6M |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | XBIT | ABVC |
|---|---|---|
| Price | $2.65 | $2.25 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 48.6K | ★ 75.8K |
| Earning Date | 11-12-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $797,916.00 |
| Revenue This Year | N/A | $735.18 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 56.52 |
| 52 Week Low | $2.09 | $0.40 |
| 52 Week High | $4.54 | $5.48 |
Technical Indicators
Market Signals| Indicator | XBIT | ABVC |
|---|---|---|
| Relative Strength Index (RSI) | 58.82 | 46.96 |
| Support Level | $2.40 | $2.21 |
| Resistance Level | $2.55 | $2.38 |
| Average True Range (ATR) | 0.10 | 0.16 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 81.58 | 46.00 |
Price Performance
Historical ComparisonAbout XBIT XBiotech Inc.
XBiotech Inc is a United States-based clinical-stage biopharmaceutical company. The company is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-inflammatory therapeutic antibodies as a treatment for cancer. Geographically, all of its operations are in the United States.
About ABVC ABVC BioPharma Inc.
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. Its drug products focus on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.